Literature DB >> 21630325

Connexin43 interacts with βarrestin: a pre-requisite for osteoblast survival induced by parathyroid hormone.

Nicoletta Bivi1, Virginia Lezcano, Milena Romanello, Teresita Bellido, Lilian I Plotkin.   

Abstract

Parathyroid hormone (PTH) promotes osteoblast survival through a mechanism that depends on cAMP-mediated signaling downstream of the G protein-coupled receptor PTHR1. We present evidence herein that PTH-induced survival signaling is impaired in cells lacking connexin43 (Cx43). Thus, expression of functional Cx43 dominant negative proteins or Cx43 knock-down abolished the expression of cAMP-target genes and anti-apoptosis induced by PTH in osteoblastic cells. In contrast, cells lacking Cx43 were still responsive to the stable cAMP analog dibutyril-cAMP. PTH survival signaling was rescued by transfecting wild type Cx43 or a truncated dominant negative mutant of βarrestin, a PTHR1-interacting molecule that limits cAMP signaling. On the other hand, Cx43 mutants lacking the cytoplasmic domain (Cx43(Δ245)) or unable to be phosphorylated at serine 368 (Cx43(S368A)), a residue crucial for Cx43 trafficking and function, failed to restore the anti-apoptotic effect of PTH in Cx43-deficient cells. In addition, overexpression of wild type βarrestin abrogated PTH survival signaling in Cx43-expressing cells. Moreover, βarrestin physically associated in vivo to wild type Cx43 and to a lesser extent to Cx43(S368A) ; and this association and the phosphorylation of Cx43 in serine 368 were reduced by PTH. Furthermore, induction of Cx43(S368) phosphorylation or overexpression of wild type Cx43, but not Cx43(Δ245) or Cx43(S368A) , reduced the interaction between βarrestin and the PTHR1. These studies demonstrate that βarrestin is a novel Cx43-interacting protein and suggest that, by sequestering βarrestin, Cx43 facilitates cAMP signaling, thereby exerting a permissive role on osteoblast survival induced by PTH.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21630325      PMCID: PMC3178733          DOI: 10.1002/jcb.23208

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  59 in total

1.  Parathyroid hormone receptor trafficking contributes to the activation of extracellular signal-regulated kinases but is not required for regulation of cAMP signaling.

Authors:  Colin A Syme; Peter A Friedman; Alessandro Bisello
Journal:  J Biol Chem       Date:  2004-12-17       Impact factor: 5.157

2.  Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation.

Authors:  Lilian I Plotkin; J Ignacio Aguirre; Stavroula Kousteni; Stavros C Manolagas; Teresita Bellido
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

3.  Osteoblast-derived PTHrP is a physiological regulator of bone formation.

Authors:  T John Martin
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

4.  Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.

Authors:  Dengshun Miao; Bin He; Yebin Jiang; Tatsuya Kobayashi; Maria A Sorocéanu; Jenny Zhao; Hanyi Su; Xinkang Tong; Norio Amizuka; Ajay Gupta; Harry K Genant; Henry M Kronenberg; David Goltzman; Andrew C Karaplis
Journal:  J Clin Invest       Date:  2005-09       Impact factor: 14.808

Review 5.  Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

Authors:  Anthony B Hodsman; Douglas C Bauer; David W Dempster; Larry Dian; David A Hanley; Steven T Harris; David L Kendler; Michael R McClung; Paul D Miller; Wojciech P Olszynski; Eric Orwoll; Chui Kin Yuen
Journal:  Endocr Rev       Date:  2005-03-15       Impact factor: 19.871

6.  Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43.

Authors:  Dong Jin Chung; Charlles H M Castro; Marcus Watkins; Joseph P Stains; Min Young Chung; Vera Lucia Szejnfeld; Klaus Willecke; Martin Theis; Roberto Civitelli
Journal:  J Cell Sci       Date:  2006-09-19       Impact factor: 5.285

Review 7.  Physiological roles of G protein-coupled receptor kinases and arrestins.

Authors:  Richard T Premont; Raul R Gainetdinov
Journal:  Annu Rev Physiol       Date:  2007       Impact factor: 19.318

8.  Oculodentodigital dysplasia-causing connexin43 mutants are non-functional and exhibit dominant effects on wild-type connexin43.

Authors:  Wendi Roscoe; Gregory I L Veitch; Xiang-Qun Gong; Emily Pellegrino; Donglin Bai; Elizabeth McLachlan; Qing Shao; Gerald M Kidder; Dale W Laird
Journal:  J Biol Chem       Date:  2005-01-10       Impact factor: 5.157

9.  Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A.

Authors:  Xun Ai; Steven M Pogwizd
Journal:  Circ Res       Date:  2004-12-02       Impact factor: 17.367

10.  Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation.

Authors:  Diane Gesty-Palmer; Minyong Chen; Eric Reiter; Seungkirl Ahn; Christopher D Nelson; Shuntai Wang; Allen E Eckhardt; Conrad L Cowan; Robert F Spurney; Louis M Luttrell; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

View more
  44 in total

1.  ERK acts in parallel to PKCδ to mediate the connexin43-dependent potentiation of Runx2 activity by FGF2 in MC3T3 osteoblasts.

Authors:  Corinne Niger; Atum M Buo; Carla Hebert; Brian T Duggan; Mark S Williams; Joseph P Stains
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-25       Impact factor: 4.249

2.  Defective signaling, osteoblastogenesis and bone remodeling in a mouse model of connexin 43 C-terminal truncation.

Authors:  Megan C Moorer; Carla Hebert; Ryan E Tomlinson; Shama R Iyer; Max Chason; Joseph P Stains
Journal:  J Cell Sci       Date:  2017-01-03       Impact factor: 5.285

3.  High bone mass in mice lacking Cx37 because of defective osteoclast differentiation.

Authors:  Rafael Pacheco-Costa; Iraj Hassan; Rejane D Reginato; Hannah M Davis; Angela Bruzzaniti; Matthew R Allen; Lilian I Plotkin
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

4.  Communication of cAMP by connexin43 gap junctions regulates osteoblast signaling and gene expression.

Authors:  Aditi Gupta; Hidayah Anderson; Atum M Buo; Megan C Moorer; Margaret Ren; Joseph P Stains
Journal:  Cell Signal       Date:  2016-05-06       Impact factor: 4.315

5.  Connexins protect mouse pancreatic β cells against apoptosis.

Authors:  Philippe Klee; Florent Allagnat; Helena Pontes; Manon Cederroth; Anne Charollais; Dorothée Caille; Aurore Britan; Jacques-Antoine Haefliger; Paolo Meda
Journal:  J Clin Invest       Date:  2011-11-07       Impact factor: 14.808

Review 6.  Shifting paradigms on the role of connexin43 in the skeletal response to mechanical load.

Authors:  Shane A Lloyd; Alayna E Loiselle; Yue Zhang; Henry J Donahue
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

7.  The regulation of runt-related transcription factor 2 by fibroblast growth factor-2 and connexin43 requires the inositol polyphosphate/protein kinase Cδ cascade.

Authors:  Corinne Niger; Maria A Luciotti; Atum M Buo; Carla Hebert; Vy Ma; Joseph P Stains
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

Review 8.  Connexin43 and the Intercellular Signaling Network Regulating Skeletal Remodeling.

Authors:  Megan C Moorer; Joseph P Stains
Journal:  Curr Osteoporos Rep       Date:  2017-02       Impact factor: 5.096

Review 9.  Connexins in the skeleton.

Authors:  Joseph P Stains; Roberto Civitelli
Journal:  Semin Cell Dev Biol       Date:  2015-12-29       Impact factor: 7.727

Review 10.  Beyond gap junctions: Connexin43 and bone cell signaling.

Authors:  Lilian I Plotkin; Teresita Bellido
Journal:  Bone       Date:  2012-10-02       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.